Menu

Supported Investigator Initiated Trials

Coordinator(s)/ scientist(s)

Disease Area

DZL Partner Site(s) involved

Title

Behr J / Günther A Diffuse Parenchymal Lung Disease (DPLD) all Exploratory efficacy and safety study of oral pirfenidone for progressive, non-IPF lung fibrosis (RELIEF in lung fibrosis)
Griese M Diffuse Parenchymal Lung Disease (DPLD) all Hydroxychloroquine (HCQ) in pediatric ILD (= children‘s interstitial lung disease; chILD)
Herold S Pneumonia and Acute Lung Injury BREATH, UGMLC GM-CSF Inhalation to improve HOst defense and Pulmonary barrier rEsoration (GI-HOPE)
Herold S / Lohmeyer J / Welte T Pneumonia and Acute Lung Injury BREATH, UGMLC Promotion of host defense and alveolar barrier regeneration by inhaled GM-CSF in patients with pneumonia-associated ARDS
Heußel C Lung Cancer BREATH, CPC-M, TLRC, UGMLC Early response capturing in the treatment of adenocarcinoma
Jobst B COPD all Imaging disease progression in COP
Kreuter M / Vogelmeier C / Herth F COPD TLRC, UGMLC Exploring efficacy of peridontal treatment on systemic inflammation and for prevention of exacerbations in patients with COPD: A multi-center, prospective, randomized, controlled, parallel-group pilot study
Reck M / Ammerpohl O / Barreto G Lung Cancer all Monitoring of patients with NLCLC – epigenetic analysis of liquid biopsies and RNA-analysis in exhaled breath condensates
Schulz H / Meiners S / Vogelmeier C / Behr J COPD CPC-M, UGMLC Proteasom Function as a Bio-Marker for COPD
Seeger W / Ghofrani A / Gall H Pulmonary Hypertension BREATH, UGMLC Influence of specific PAH medication on right ventricular function in patients with pulmonary arterial hypertension
Tümmler B Cystic Fibrosis / Mucoviscidosis BREATH, TLRC, UGMLC Orkambifacts – Intestinal current measurements (ICM) to evaluate the activation of mutant CFTR in treated with lumacaftor in combination with ivacaftor.
Vogel-Claussen J Radiology / Pulmonale Hypertronie BREATH, CPC-M, UGMLC, TLRC Change-MRI – Phase III diagnostic trial to demonstrate that functional lung MRI can replace VQ-SPECT in a diagnostic strategy for patients with suspected CTEPH.
Vogelmeier C  COPD ARCN, BREATH, UGMLC Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with moderate to severe COPD – A randomised, double-blind, parallel, multicentre, phase IIa pilot study
Zabel P / Herth F / König I / Rabe K / Welte T  COPD ARCN, BREATH, TLRC Evaluation of non-invasive pursed-lip breathing ventilation in advanced COPD
chevron-down